.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 3,987,200

« Back to Dashboard

Claims for Patent: 3,987,200

Title: Method for increasing cardiac contractility
Abstract:N-Mono or dihydroxyphenylalkyl dopamine derivatives and salts thereof are inotropic agents useful in a method for treatment of acutely depressed cardiac insufficiency.
Inventor(s): Tuttle; Ronald R. (Indianapolis, IN), Mills; Jack (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:05/541,179
Patent Claims: 1. The method for increasing cardiac contractility in a warm-blooded mammal suffering from acutely depressed cardiac contractility which comprises administering to said mammal at a rate of between 0.5 and 10 micrograms per kilogram of body weight per minute a compound of the formula ##SPC5##

wherein

R and R.sub.1 are hydrogen or methyl;

R.sub.2 and R.sub.3 are hydrogen or hydroxy, at least one of R.sub.2 and R.sub.3 being hydroxy;

n is 1 or 2;

subject to the limitation that when n is 2, R.sub.2 is hydrogen and R.sub.3 is hydroxy, one of R or R.sub.1 is hydrogen and the other is methyl; and the pharmaceutically acceptable acid addition salts thereof with mineral acids.

2. The method of claim 1 wherein the compound administered is a compound of the formula ##SPC6##

wherein

R and R.sub.1 are hydrogen or methyl;

R.sub.2 and R.sub.3 are hydrogen or hydroxy, at least one of R.sub.2 and R.sub.3 being hydroxy;

n is 1 or 2;

subject to the limitation that when n is 2, R.sub.2 is hydrogen and R.sub.3 is hydroxy, one of R or R.sub.1 is hydrogen and the other is methyl; with the further limitations that when n is 2 and R.sub.2 and R.sub.3 are both hydroxy, then R.sub.1 is hydrogen, and when n is 1, R.sub.2 is hydrogen and R.sub.3 is hydroxy, then R and R.sub.1 are both hydrogen; and the pharmaceutically acceptable acid addition salts with mineral acids.

3. The method of claim 2 wherein the compound administered is 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methyl-n-propyl]-.beta.-phenethylam ine hydrochloride.

4. The method of claim 2 wherein the compound administered is levo-3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methyl-n-propyl]-.beta.-phenet hylamine hydrochloride.

5. The method of claim 2 wherein the compound administered is 3,4-dihydroxy-N-[3-(3-hydroxyphenyl-n-propyl]-.beta.-phenethylamine hydrochloride.

6. The method of claim 2 wherein the compound administered is 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-n-propyl]-.alpha.-methyl-.beta.-phene thylamine hydrochloride.

7. The method of claim 2 wherein the compound administered is 3,4-dihydroxy-N-[2-(3,4-dihydroxyphenyl)ethyl]-.beta.-phenethylamine.

8. The method of claim 2 wherein the compound administered is 3,4-dihydroxy-N-[3-(3,4-dihydroxyphenyl)-n-propyl]-.beta.-phenethylamine hydrochloride.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc